Pier 70 Ventures

What Pier 70 Ventures does

Pier 70 Ventures is a privately-held venture capital firm founded in 2017 and headquartered in Seattle, Washington, with additional offices in Indianapolis, New York, and San Francisco. The firm invests through its INpact Fund in early-stage healthcare companies, focusing on disruptive technologies spanning biotech, medical devices, digital health, and AI-enabled health solutions. It explicitly targets entrepreneurs building diverse teams, differentiating on the thesis that ethnically diverse leadership drives superior financial outcomes, citing McKinsey research on a 35% EBITDA margin advantage for diverse Fortune 1000 companies.

The firm does not develop proprietary technology; its "product" is capital, mentorship, and network access. Portfolio companies receive strategic guidance from managing partners with deep operating backgrounds at Boeing, Eli Lilly, and successful exits such as OpenStudy, as well as introductions to Fortune 200 leaders, university contacts, and government contracting pathways. Disclosed portfolio companies include DermaSensor (AI-powered skin cancer detection), Antigenix Therapeutics, Adipo Therapeutics, Amplified Sciences, Acclinate, GoMedhaul, Movn Health, and Nestre Performance, with check sizes ranging from $400K to co-investments in $16M Series B rounds.

The business model is classic venture fund management. Pier 70 raises capital from institutional and corporate limited partners and earns returns through capital appreciation in portfolio companies and eventual exits via acquisitions or IPOs. Distribution is relationship-driven rather than marketing-led, relying on the partners' networks, referrals, industry events, and public-private co-investment programs such as the NJ Innovation Evergreen Fund. The firm is led by four managing partners (R. Miller Adams, Preetha Ram, Shaun Hawkins, and Robert H. Balk) with combined experience exceeding 40 years in venture capital and corporate strategy.

Name

Pier 70 Ventures

Legal name

Pier 70 Ventures

Website

https://pier70ventures.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Pier 70 Ventures is a Seattle-based venture capital firm founded in 2017 that invests through its INpact Fund in early-stage healthcare companies developing AI-enabled, data-driven, and patient-centric technologies, with a focus on diverse founding teams.

Ownership category

akta.pro rank

Product category

Venture Capital (Healthcare Focus)

NAICS

Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Development Finance & Blended Finance Facilities (BPADAOAD), Venture Capital Fundraising Placement (FSAEALAC)

Keywords

• Venture capital
• Healthcare investing
• Early-stage funding
• Impact investing
• Healthtech startups

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D, Others

Revenue model

1. Venture Capital Fund Management: Pier 70 Ventures generates returns for its limited partners through equity investments in early-stage healthcare companies. The firm earns returns through capital appreciation and exits from portfolio companies, typically through acquisitions or IPOs. The investment strategy emphasizes supporting diverse teams creating the Future of Health through patient-centric, wellness-focused, data-driven, cloud-enabled, and AI-enabled technologies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Pier 70 Ventures is a venture capital firm that manages the INpact Fund to invest in early-stage healthcare companies led by diverse teams. The firm provides capital, mentorship, and access to global connections (Fortune 200 leaders, university, and government networks) to portfolio companies building patient-centric, data-driven, AI-enabled, and cloud-enabled healthcare innovations. Returns are generated for limited partners through equity appreciation and exits from portfolio companies.

Product overview

Pier 70 Ventures operates as a venture capital firm with a single fund structure called the INpact Fund. The firm invests in early-stage healthcare companies led by diverse teams, providing capital, mentorship, and access to global connections. Their investment strategy emphasizes impact-driven innovation in healthcare technology, with a focus on companies developing patient-centric, data-driven, and AI-enabled solutions. The INpact Fund is the primary investment vehicle through which Pier 70 deploys capital into portfolio companies including Adipo Therapeutics, Antigenix Therapeutics, Amplified Sciences, Acclinate, DermaSensor, GoMedhaul, Movn Health, and Nestre Performance.

Differentiator

Problem solved

Functional benefit

Brands

• INpact Fund: The Pier 70 Ventures INpact Fund is where innovation meets impact. It invests in early-stage companies led by diverse teams creating the Future of Health: Patient Centric, Wellness Focused, Data Driven, Connected, On the Cloud, AI Enabled.

Products and services

• INpact Fund The INpact Fund is Pier 70 Ventures' core venture capital fund that invests in early-stage companies led by diverse teams creating the Future of Health: patient-centric, wellness-focused, data-driven, connected, cloud-enabled, and AI-enabled healthcare innovations. The fund deploys capital into portfolio companies such as Adipo Therapeutics, Antigenix Therapeutics, Amplified Sciences, Acclinate, DermaSensor, GoMedhaul, Movn Health, and Nestre Performance.

Quantifiable outcome

• Over $1 billion in capital put to work across 30 direct investments, 40 fund investments, and 500+ portfolio companies

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Define Ventures: Early-stage digital health venture firm investing across health tech categories. Directly comparable to Pier 70 as a specialist, early-stage healthcare VC with a thematic, thesis-driven approach to portfolio construction.
• Flare Capital Partners: Early-stage healthcare technology VC firm leading seed and Series A rounds in digital health, health IT, and tech-enabled services. Similar stage and sector focus to Pier 70.
• Town Hall Ventures: Healthcare-focused VC investing in companies serving underserved populations, with an explicit diversity and health-equity thesis. Closely mirrors Pier 70's healthcare + diversity combination.
• Arboretum Ventures: Healthcare-focused VC investing in early- and growth-stage companies across medical devices, diagnostics, digital health, and healthcare services. Similar size, stage, and sector focus as Pier 70.

Broad incumbents

• Khosla Ventures: Large early-stage VC with material healthcare, biotech, and digital health deployment. Comparable as a thematic investor in transformative healthtech but with much larger fund vehicles.
• Norwest Venture Partners: Multi-stage VC with a dedicated healthcare practice spanning medical devices, digital health, and services. Overlaps Pier 70's sector focus but with broader stage range and larger fund sizes.
• GV (Google Ventures): Large multi-stage venture firm with a substantial healthcare and life sciences practice. Overlaps with Pier 70 on healthcare/digital health but operates across all stages and sectors.
• Optum Ventures: Corporate venture arm of Optum/UnitedHealth Group investing in early- and growth-stage healthcare companies. Comparable healthcare-focused VC investor but with corporate balance-sheet backing.
• Andreessen Horowitz Bio + Health Fund: Mega-VC with a dedicated bio/health fund targeting early-stage healthcare, biotech, and digital health companies. Competes for the same healthcare deal flow as Pier 70 but at substantially greater scale.

Emerging players

• Health Equity Ventures: Emerging healthcare VC focused on health equity and diverse founders, overlapping Pier 70's diversity-and-healthcare thesis but at an earlier stage of platform development.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pier 70 Ventures